Recombinant mouse IL-6 protein - Bioactive cytokine

Recombinant cytokine, source: E. coli

SPECIFICATIONS

Specifications

Source
E. coli
Species
Mouse
Synonyms
B cell hybridoma growth factor
Interleukin HP-1
Accession sequence

P08505

Protein size
187 a.a. (F25-T211)
Molecular weight
~ 22 kDa
Carrier
Carrier-free
Tag
Tag-free
Purity
≥95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Tris-based buffer (pH 8.0), sucrose, EDTA, Tween-80 and mannitol

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.22 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested)

ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Recombinant mouse IL-6
  • Cat code: 
    rcyec-mil6
  • Quantity: 
    10 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

The proinflammatory cytokine IL-6 is one of the most important mediators in the regulation of the immune response, hematopoiesis, and inflammation [1]. It plays roles in chronic inflammation, autoimmune diseases, and cancer. In addition, it has been reported to be involved in the cytokine storm triggered by the corona virus disease 2019 (COVID-19) [2].
 

IL-6 exerts its action by first binding to the IL-6 receptor (IL-6R). The complex of IL-6 and IL-6R associates with the signal-transducing membrane protein gp130, thereby inducing its dimerization. This leads to the downstream activation by phosphorylation of certain tyrosine kinases within the Janus family (JAK1, JAK2, and Tyk2). Subsequently, activated JAKs induce phosphorylation, dimerization and translocation of the signal transducer and activator of transcription 3 (STAT3) to the nucleus where it binds enhancer elements of IL-6 inducible genes [3]. Considering the various properties of this pleiotropic cytokine, the IL-6–STAT3 signaling axis is now considered a major target for the treatment of inflammatory diseases [2].

 

References:

1. Kang S. et al., 2015. Therapeutic uses of anti-interleukin-6 receptor antibody. Int. Immunol. 27: 21-9.
2. Hirano T., 2021. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 1;33(3):127-148.
3. Murray P., 2007. The JAK-STAT Signaling Pathway: Input and Output Integration. J. Immunol. 178:2623-9.

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?